Plenary Session

382 Episodo

1. 1.22 Elo-Pom-Dex, Immunotherapy Combos, Inherent Bias, and the FDA with Dr. Erick Turner

   Publicado: 13/11/2018
2. 1.21 Nab-Paclitaxel in CCA, OS of PALOMA-3, Transparency, and Dr. Talal Hilal's Advice for Trainees

   Publicado: 6/11/2018
3. 1.20 Precision Oncology: Some Benefit, Mostly Hype and Mentorship with Dr. Andrae Vandross

   Publicado: 30/10/2018
4. 1.19 BONUS! Introduction to Cancer Drug Policy

   Publicado: 26/10/2018
5. 1.18 IMpassion130 and Hot-Spotting with Dr. Brian Chan

   Publicado: 23/10/2018
6. 1.17 BONUS! Interpretation of Cancer Clinical Trials

   Publicado: 22/10/2018
7. 1.16 BONUS! Crowdsourcing Data Analysis and Medical Reversal: Why 40% of What We Do is Wrong

   Publicado: 17/10/2018
8. 1.15 Minimally Effective Treatments, CheckMate 331, and Dr. Adam Obley on Low-Value Healthcare

   Publicado: 16/10/2018
9. 1.14 BONUS! Immunotherapy in Desperation and the Pennington Lecture: Myths of Medicine and Marketing

   Publicado: 12/10/2018
10. 1.13 KEYNOTE-189, Dr. Talal Hilal on MRD, and Medical Education with Dr. Adam Cifu

    Publicado: 8/10/2018
11. 1.12 BONUS! Evidence-Based Medicine Has Been Hijacked in Oncology

    Publicado: 3/10/2018
12. 1.11 Peanut Gallery, Research Parasites, Appendectomies, HRQoL and PFS, Dr. Bishal Gyawali

    Publicado: 2/10/2018
13. 1.10 Criticism via Twitter, PACIFIC, PCI for CAD, and Dr. Rebecca Cooney of The Lancet

    Publicado: 25/9/2018
14. 1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints

    Publicado: 20/9/2018
15. 1.08 Hyperprolific authors, NCCN with Jeff Wagner, and Dr. Renee Dversdal on Ultrasounds

    Publicado: 14/9/2018
16. 1.07 Adjuvant Sunitinib in RCC, future of EBM with Dr. John Mandrola

    Publicado: 11/9/2018
17. 1.06 RELEVANCE, Jenny Gill, and Dr. Catherine Livingston of the Oregon Health Authority

    Publicado: 7/9/2018
18. 1.05 Cost and Efficacy of Cancer Drugs, ECHELON-1, Dr. Derrick Tao, and EBM with Dr. Martha Gerrity

    Publicado: 5/9/2018
19. 1.04: Nutritional Epi, Lenvatinib, Nivo and Ipi for Melanoma, and Dr. Avi O'Glasser

    Publicado: 30/8/2018
20. 1.03: RWE, Right to Try, Talazoparib, Nivolumab, and Dr. Andrae Vandross

    Publicado: 21/8/2018